Hot Investor Mandate 2: Crossborder Fund Looks Early for Healthcare Products

9 Feb

A venture capital firm founded in 2016 with offices in the USA and China generally invests $1-5M (USD) of equity capital and aims to make 3-5 investments per year, but this is not a fixed number. In general, the firm participates in seed and series A funding rounds. The firm looks at companies of all parts of the world and has a strong preference for companies that have market opportunities in Asian markets, particularly China. The firm’s China office will provide companies with the resources they need for successful market entry.

The firm looks at all sectors pertaining to healthcare, including biotech therapeutics, R&D services, diagnostics, medical devices, and digital health. While the firm’s focus is in early-stage companies, it takes a very opportunistic viewpoint. In therapeutics, the firm will look at products of all stages from pre-clinical to phase III, and is open to all indications. In terms of medical devices, the firm will consider both 510k and PMA devices. In addition, the firm will also consider products that are already on the market.

The firm is open to both public and private companies, and expects them to have an experienced management team with a strong exit strategy. The firm requires a board seat in all portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: